Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
2.

Mortality after surgery in Europe: a 7 day cohort study.

Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A; European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology.

Lancet. 2012 Sep 22;380(9847):1059-65. doi: 10.1016/S0140-6736(12)61148-9.

3.

Hyperprolactinemia--an unusual initial manifestation of multiple sclerosis.

Debelić D, Sepcić J, Rudez J, Materljan E.

Eur Neurol. 1997;38(2):128-9. No abstract available.

PMID:
9286637
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk